What is the global market size of Dry Eye Disease Market?

Dry Eye Disease Market size was valued at USD 5.13 billion in 2021 and is poised to grow from USD 5.53 billion in 2022 to USD 10.92 billion by 2030, growing at a CAGR of 7.85% in the forecast period (2023-2030).

Dry Eye Disease Companies

Q: Which region accounted for the largest share in Global Dry Eye Disease Market?

The global dry eye disease market is studied on the basis of geography as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Due to the high prevalence of dry eye diseases and the ease with which solutions are available in the region, North America is expected to hold a significant share of the dry eye disease market. In this multi-screen world, people of all ages can be found. Computer or digital screen use may result in less blinking, which may contribute to symptoms of dry eye disease (DED), thereby increasing the demand for better and more effective DED therapeutics, which is expected to fuel growth in the North American region studied.

Dry Eye Disease Market Competitive Landscape

Dry Eye Disease Market Top Company Profiles

Allergan plc (now part of AbbVie Inc.)
Novartis AG
Santen Pharmaceutical Co., Ltd.
Johnson & Johnson
Otsuka Pharmaceutical Co., Ltd.
Shire (now part of Takeda Pharmaceutical Company Limited)
Sun Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
Alcon Inc. (a subsidiary of Novartis AG)
AbbVie Inc.
Akorn, Inc.
Nicox SA
Mitotech S.A.
Tarsus Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc.
Novaliq GmbH
Oyster Point Pharma, Inc.
AFT Pharmaceuticals Ltd.
OcuSoft, Inc.
Eyenovia, Inc.

Dry Eye Disease Market

FAQs

Dry Eye Disease Market size was valued at USD 5.13 billion in 2019 and is poised to grow from USD 5.53 billion in 2023 to USD 10.92 billion by 2031, growing at a CAGR of 7.85% in the forecast period (2024-2031).

The market for dry eye disease is moderately competitive. In terms of market share, the market is currently dominated by a few major players. With the growing geriatric population and high disease prevalence, a few new smaller players are expected to enter the market in the coming years. AbbVie Inc. (Allergan PLC), Alcon Inc., and Santen Pharmaceutical Co. are among the market's major players. 'Allergan plc (now part of AbbVie Inc.)', 'Novartis AG', 'Santen Pharmaceutical Co., Ltd.', 'Johnson & Johnson', 'Otsuka Pharmaceutical Co., Ltd.', 'Shire (now part of Takeda Pharmaceutical Company Limited)', 'Sun Pharmaceutical Industries Ltd.', 'Bausch Health Companies Inc.', 'Alcon Inc. (a subsidiary of Novartis AG)', 'AbbVie Inc.', 'Akorn, Inc.', 'Nicox SA', 'Mitotech S.A.', 'Tarsus Pharmaceuticals, Inc.', 'Kala Pharmaceuticals, Inc.', 'Novaliq GmbH', 'Oyster Point Pharma, Inc.', 'AFT Pharmaceuticals Ltd.', 'OcuSoft, Inc.', 'Eyenovia, Inc.'

Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common ophthalmic disorder that affects about 360 million people worldwide. Patients complain of dryness, irritation, redness, fatigue, and blurred vision. The prevalence varies with age, but it is increasing in both the young and old populations due to increased screen time, poor diet, increased use of contact lenses, and an increase in the number of LASIK surgeries. The ability of the lachrymal glands to produce tears decreases with age, resulting in dry eyes. One of the key factors contributing to the growth of the dry eye drugs market is the rising incidence of dry eye disease due to an ageing population.

One of the leading market trends in the dry eye disease market has been an increase in R&D spending, successful clinical trials, and increased new product approvals. A large number of companies are involved in clinical trials, such as Aldeyra Therapeutics, Inc.'s pipeline candidate Reproxalap, which is currently in Phase - III. This type of initiative is expected to drive the dry eye disease treatment market's revenue generation.

The dry eye disease market is studied on the basis of geography as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Due to the high prevalence of dry eye diseases and the ease with which solutions are available in the region, North America is expected to hold a significant share of the dry eye disease market. In this multi-screen world, people of all ages can be found. Computer or digital screen use may result in less blinking, which may contribute to symptoms of dry eye disease (DED), thereby increasing the demand for better and more effective DED therapeutics, which is expected to fuel growth in the North American region studied.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Dry Eye Disease Market Size, Share, Growth Analysis, By Product(Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues), By Distribution Channel(Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies), By Region - Industry Forecast 2024-2031

Dry Eye Disease Market Competitive Landscape

Dry Eye Disease Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Dry Eye Disease Market Size, Share, Growth Analysis, By Product(Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues), By Distribution Channel(Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Pharmacies), By Region - Industry Forecast 2024-2031

Dry Eye Disease Market Competitive Landscape

Dry Eye Disease Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Dry Eye Disease Market?

Who are the key vendors in the Dry Eye Disease Market?

What is the key driver of Dry Eye Disease Market?

What is the key market trend for Dry Eye Disease Market?

Which region accounted for the largest share in Dry Eye Disease Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300